The government will soon announce the first 10 medications that will be subject to price negotiations with Medicare under a new law.

In recent months ominous ads about prescription drugs have flooded the TV airwaves.

Health insurers and medical providers are battling over who should supply high-cost infusion drugs for patients, with the tussle over profits now spilling into statehouses across the country.

Millions of adults in the United States are not taking their medications as prescribed because of costs, according to a new report from the US Centers for Disease Control and Prevention.

Patients who take the autoimmune disease treatment Humira may see some price relief when several lower-cost, biosimilar versions of the AbbVie drug reach the U.S. market in July.

A largely hidden flow of money between major consulting conglomerates and PBMs compromises the firms’ ability to choose prescription drug benefits for employers.

Sens. Bernie Sanders, I-Vermont, and Bill Cassidy, R-Louisiana, reached a deal on new legislation that aims to increase access to generic drugs and impose transparency measures on pharmacy middlemen.

Cigna Group is offering clients a clearer view of how much they pay for drugs through its prescription plans, as the industry responds to rising Washington scrutiny and competition from smaller rivals touting greater transparency.

Senators and witnesses at today's Senate Finance Committee on PBMs took aim at PBMs for their role in what they say keeps drug prices high for consumers and for the Medicare program.

The National Association of Chain Drug Stores and the National Community Pharmacists Association are lauding the introduction of S. 1038, the Drug Pricing Transparency in Medicaid Act, introduced by U.S. Sens. Peter Welch (D-Vt.) and Roger Marshall (R-Kan.).